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Purpose: Early results of a prospective study that compared surgical revascularization a d 
thrombolysis for lower extremity arterial and graft occlusions have been published. This 
report details the final results in patients who have native artery occlusions. 
Methods: Two hundred thirty-seven patients who had lower extremity ischemia s a result 
of iliac-common femoral (IF; 69 patients) or superficial femoral-popliteal (FP; 168 
patients) occlusion, and had symptomatically deteriorated within the past 6 months were 
randomized to catheter-directed hrombolysis (150 patients) or surgical revascularization 
(87 patients). After diagnostic arteriographic examination but before randomization, the 
optimal surgical procedure was determined. Lytic patients were randomized to recombi- 
nant tissue plasminogen activator (rt-PA; 84 patients) or urokinase (UK; 66 patients). 
Recurrent ischemia, morbidity, amputation, and death rates were determined at 30 days, 
6 months, and 1 year, and were analyzed on an intent-to-treat basis. 
Results: For patients randomized to lysis, a catheter was properly positioned and the lyric 
agent delivered in 78%. This provided areduction in the predetermined surgical procedure 
in 58% of patients who had an FP occlusion and 51% of those who had an IF occlusion. 
rt-PA and UK were equally effective and safe, but lysis time was shorter with rt-PA (8 vs 
24 hr; p < 0.05). At I year, the incidence of recurrent ischemia (64% vs 35%; p < 0.0001) 
and major amputation (10% vs 0%; p = 0.0024) was increased in patients who were 
randomized to lysis. Factors associated with a poor lytic outcome included FP occlusion, 
diabetes, and critical ischemia. No differences in mortality rates were observed at 1 year 
between the lysis and surgical groups. 
Conclusion: Surgical revascularization forlower extremity native artery occlusions is more 
effective and durable than thrombolysis. Thrombolysis used initially provides areduction 
in the surgical procedure for a majority of patients; however, long-term outcome is 
inferior, particularly for patients who have an FP occlusion, diabetes, or critical ischemia. 
(J Vase Surg 1996;24:513-23.) 
Catheter-directed thrombolysis of occluded arte- 
rial segments i now a frequent and well-recognized 
treatment for patients who have leg ischemia. Numer- 
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ous authors have reported salutary results when 
thrombolysis is used as the primary treatment for 
chronic peripheral arterial occlusions that involve the 
legs; however, prospective comparisons with the al- 
ternative of surgical revascularization are limited. 1
The Surgery versus Thrombolysis for Ischemia of 
the Lower Extremity (STILE) Trial was a prospective 
randomized trial designed to investigate the compara- 
tive results of traditional surgical revascularization 
with those of catheter-directed thrombolytic therapy. 
The study enrolled patients who had either a bypass 
graft or native artery occlusion, and an initial report of 
overall results of the study was published. 2 Since the 
initial STILE publication, the long-term (1 year) 
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follow-up results and subgroup analyses for bypass 
grafts, technical parameters ofsuccessful lyric therapy, 
and native artery occlusions are now available. This 
report details the final analysis of patients who had 
native artery occlusions. 
PATIENTS 
The STILE trial was a multicenter, prospective, 
randomized trial that compared optimal surgical re- 
vascularization with catheter-directed thrombolysis 
with the use of either urokinase (UK) or recombinant 
tissue plasminogen activator (rt-PA) for nonembolic 
leg ischemia. Thirty-one centers in the United States 
and Canada participated in the trial. Three hundred 
ninety-three patients were entered into the trial. The 
primary and secondary hypotheses, the details of 
study design, the statistical analyses, and the overall 
short-term results have been published previously. 2 
This report concerns the subset of patients who had 
native artery occlusions, pecifically 237 patients who 
had either an iliac-common femoral artery (IF) oc- 
clusion or a superficial femoral-popliteal artery (FP) 
occlusion. 
All patients who had new or progressive ischemic 
symptoms of less than 6 months' duration and an 
angiographically documented nonembolic occlusion 
of a major native artery that supplied the legs were 
potential candidates. Each patient signed an informed 
consent statement before being enrolled. Patients 
who were eligible but not randomized (ENR) be- 
cause of patient or investigator decision were tabu- 
lated and reported to the study center. Demographic 
information, ischemic symptoms, and duration of 
symptoms were recorded for all patients. Symptoms 
of leg ischemia were defined and categorized accord- 
ing to standards recommended by the SVS and 
ISCVS? 
The optimal surgical procedure for revasculariza- 
tion was determined by the surgeon investigator n 
the basis of the diagnostic arteriogram and was 
recorded before randomization. The primary occlu- 
sive lesion was categorized as aorta, iliac, common 
femoral, profunda femoris, superficial femoral, 
popliteal, or distal (infrapopliteal). Patients then were 
randomized by telephone atthe Collaborative Studies 
Coordinating Center, Department of Biostatistics, 
University of North Carolina. Patients were random- 
ized to one of three treatment groups: (1) intraarterial 
catheter-directed thrombolysis with rt-PA 0.1 
mg/kg/hr  for as many as 12 hours, which was 
modified to 0.05 mg/kg/hr  for as many as 12 hours 
on September 1, 1992; (2) intraarterial catheter- 
directed thrombolysis with UK 250,000 unit bolus 
followed by 4000 units/min for 4 hours, and then 
2000 units/min for as many as 36 hours; and (3) 
surgical revascularizarion. 2 
For patients who were randomized tothromboly- 
sis, lysis was instituted only after properly positioning 
an infusion catheter into the occluded artery. Failure 
to cannulate the arterial occlusion was considered a 
lyric failure. The choice of the type of catheter that was 
used for delivery of the lyric agent (endhole, sidehole, 
multiple, or single catheters) was made at the discre- 
tion of the investigator. Thrombolysis patients re- 
ceived heparin 5000 IU as an intravenous bolus at the 
rime infusion was initiated, followed by 1000 IU/hr 
intravenously, which was ritrated to maintain the 
activated partial thromboplastin rime at 1.5 to 2.0 
times control. Intraarterial heparin was administered 
according to individual institutional guidelines. Hep- 
arin was continued until either a contraindication to 
heparin therapy existed or optimal postthrombolytic 
management was implemented. Patients who were 
randomized to thrombolysis also received 325 mg 
aspirin orally at the time of randomization a d then 
daily. Arteriograms were obtained at 4 and 8 hours 
after the start of thrombolysis and at completion. 
Vascular patency was defined as restoration ofluminal 
continuity and was categorized ateach interval and at 
the completion angiographic s an? 
When vessel patency was angiographically estab- 
lished, thrombolysis was terminated. Any underlying 
native artery stenosis that was identified as a probable 
cause of the occlusion was corrected either by endo- 
vascular intervention (balloon angioplasty, atherec- 
tomy) or by surgical revision. These corrections were 
considered secondary procedures and as a part of a 
successful thrombolysis procedure. Any procedure 
that was required because lysis failed to establish 
arterial patency was termed asubsequent procedure 
and was considered as a failure of the thrombolysis 
procedure. For patients who were randomized to 
surgical revascularization, the actual procedure per- 
formed was recorded. 
Primary endpoints 
Composite clinical outcome. The primary end- 
point was the occurrence of at least one event of a 
composite clinical outcome. Listed below are the 
components ofthe composite clinical outcome. 
A) Death 
B) Major amputation (above-knee orbelow-knee 
amputation) 
C) Ongoing or recurrent ischemia--failure of the 
revascularization procedure to improve perfusion, or 
thrombosis of an initially successful procedure 
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D) Major complications 
1) Life-threatening hemorrhage, ither intra- 
cranial or blood-loss producing hypotension, requir- 
ing resuscitation; 
2) Perioperative complications, e.g., cerebro- 
vascular accident, myocardial infarction, pulmonary 
edema, congestive heart failure 
3) Renal failure requiring dialysis 
4) Serious anesthesia-related complications 
5) Vascular complications, e.g., dissection, 
perforation, pseudoaneurysm, or occlusion requiring 
unplanned or emergent surgical repair 
6) Postintervention wound complications; 
wound infection that requires ystemic antibiotics or 
dedicated wound care, or hematoma requiring drain- 
age, reexploration, or a blood transfusion. 
The occurrence of any of these events was consid- 
ered an adverse outcome, regardless of cause, and the 
patient was classified as having reached a primary 
endpoint. 
Secondary endpoints 
Reduction in surgery. The impact of catheter- 
directed thrombolysis on reduction of reqttired sur- 
gical revascularization was evaluated by comparing 
the actual surgical procedure performed with the 
procedure planned before randomization. A reduc- 
tion in surgical revascularization was defined as a 
decrease of at least one level of intervention from that 
originally planned. Procedures are listed in order of 
increasing intervention i Table I. 
Major amputation or death. The endpoint of 
death or major amputation was analyzed at I year. The 
impact of duration of ischemia, critical ischemia 
defined as either est pain or ischemic ulceration/tis- 
sue necrosis (Grade II, III SVS/ISCVS), and the 
presence of diabetes on this endpoint also was con- 
sidered. 3 
Per-protocol analyses. Selective per-protocol 
analyses (analyses that included only those patients 
who actually received the treatment specified at ran- 
domization) also were performed on the composite 
clinical outcome and the combined endpoint of major 
amputation and death. 
Statistical analysis. All statistical tests were two- 
sided and were performed at the 0.05 level of signifi- 
cance unless otherwise stated. Comparisons of con- 
tinuous baseline variates between the vessel groups 
were performed with standard analysis of variance 
techniques. Discrete categoric variates were tested 
with Fisher's exact test 4 in cases of tables that had 
sparse cells, or with either the Pearson )~2 or Cochran- 
Mantel-Haenszel )~2 test swhen cell frequencies were 
Table I. Interventional procedures in order 
of increasing intervention 
No intervention performed 
Further thrombolysis 
Intravascular mechanical repair of native vessel or existing 
bypass graft, i.e., balloon angioplasty 
Thrombectomy orendarterectomy of native vessel, or 
thrombectomy and revision/repair ofexisting bypass 
graft 
Placement ofnew bypass graft or replacement of existing 
graft 
Transmetatarsal amputation r loss of digit(s) 
Below-knee amputation 
Above-knee amputation 
adequate, and Breslow-Day Z2 statistics 6 for testing 
for treatment by subgroup interactions. 
Evaluation of primary and secondary endpoints 
was performed at 30 days, 6 months, and 1 year. 
Efficacy analyses were stratified by vessel type: IF and 
FP. A small cohort of patients who had aorta, pro- 
funda femoris, or distal occlusions were not analyzed 
further. The stratified Cochran-Mantel-Haenszel )~2 
test and associated relative risk with 95% confidence 
intervals were used for both the primary and second- 
ary endpoints analyses. When stratification produced 
sparse cells with either few or no events across 
treatment groups, Fisher's exact est was used. Logis- 
tic regression models were fitted for the death or 
major amputation endpoint at I year for the com- 
bined native vessel group with the explanatory vari- 
ables diabetes, duration ofischemia, critical ischemia, 
and median age. 7 No adjustment for multiple testing 
of all other test results was made. SAS version 6.10 was 
used to perform the primary statistical nalysis and to 
generate all tables and listings. 
RESULTS 
Two hundred sixty-one patients who had symp- 
tomatic leg ischemia as a result of a native artery 
occlusion were entered into the study. The location of 
the occlusive lesion is listed in Table II. Of the 261 
patients who had leg ischemia caused by a native 
artery occlusion, 237 had either an IF (69) or FP 
(168) occlusion. 
Of these 237 patients, 160 (68%) were male and 
77 (32%) female. The patients' median age was 66 
years. Ischemic symptoms included claudication in 
34%, rest pain in 35%, and ischemic ulceration or 
tissue necrosis in 31%. Risk factors for atherosclerotic 
occlusive disease were a smoking history in 79%, 
hypertension i 57%, diabetes mellitus in 43%, and 
hypercholesterolemia in 30%. The mean duration of 
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Table II. Arteriographic findings 
Native artery (n = 261) 
Study occlusion n % 
Aortic 5 1.9 
Iliac 52 19.9 
Femoral 17 6.5 
Profunda 3 1.1 
SFA 131 50.2 
Popliteal 37 14.2 
Distal 10 3.8 
Missing/invalid 6 2.3 
SFA, Superficial femoral artery. 
ischemia was 59 days; 20% of patients had a progres- 
sion or onset of ischemic symptoms of less than 14 
days in duration. 
Patients who had IF occlusions were more likely to 
be younger (62 years vs 65 years; p -- 0.034), have had 
a previous bypass in the study limb (p -- 0.0015), and 
to have been a smoker (p = 0.0007), or to currently 
be a smoker (p-- 0.0011). Patients who had an FP 
occlusion were more likely to have diabetes 
(p=0.0016) or have critical limb ischemia 
(p -- 0.0001). One hundred eighty-three ENR pa- 
tients also were recorded. Clinical characteristics, 
ischemic symptoms, and risk factors were similar to 
those of randomized patients, with the exception that 
they were more likely to be Caucasian and to have 
undergone a previous bypass procedure in the study 
limb. ENR patients were less likely to be current 
smokers. 
One hundred fifty patients were randomized to 
receive catheter-directed thrombolysis, whereas 87 
were randomized to surgical revascularization. There 
were no differences in baseline variables (previously 
published 2) between the surgical and thrombolytic 
groups. Of those patients randomized to thromboly- 
sis, 84 were randomized to rt-PA and 66 to UK. In 
patients who were randomized to thrombolysis, a 
guidewire was successfully passed, acatheter properly 
positioned, and a lytic agent delivered in 78%. Overall, 
patency was reestablished in 55% of patients (IF, 57%; 
FP, 55%). UK and rt-PA established arterial patency 
with equal frequency (49% vs 59%). Lysis time with 
rt-PAwas a mean of 8 hours versus amean of 24 hours 
for UK (p < 0.05). A secondary procedure was re- 
quired after 55% of lysis procedures, 75% being 
endovascular procedures (i.e., balloon dilatation, 
stent placement, etc.). The magnitude of these pro- 
cedures compared with the "best" surgical procedure 
as determined before randomization was reduced in 
58% of patients who had an FP occlusion and in 51% 
of patients who had an IF occlusion. 
The best surgical procedure chosen before ran- 
domization was performed in98% of surgical patients. 
The predominant procedure was a bypass grafting 
procedure, which was performed in 86%. After sur- 
gery, anticoagulants were used in 27% of the patients 
and antiplatelet agents in 51%. 
Composite clinical outcome. Thirty-day, 
6-month, and 1-year esults of the composite clinical 
outcome on an intent-to-treat basis are listed in Table 
III. At 30 days a statistically significant increase in 
ongoing or recurrent ischemia nd composite clinical 
outcome for the thrombolytic arm is evident overall 
and in both the IF and FP subgroups. At 6 months, a
benefit in major amputation rates for surgical revas- 
cularization compared with thrombolysis emerges in 
the FP subgroup (0% vs 9%) and overall. All of the 
above findings persist at the 1-year time point. 
A per-protocol analysis (Table IV) at 1 year that 
includes only patients who actually received the lyric 
agent therapy demonstrates the composite clinical 
outcome and ongoing or recurrent ischemia in the IF 
subgroup to be equivalent for the two treatment 
groups. The incidence of morbid events m the IF 
subgroup after thrombolysis, however, is increased 
(5% vs 28%), predominantly asa result of the increased 
incidence of vascular complications after thrombolysis 
was performed (4% vs 15%). The difference in the 
composite clinical outcome, ongoing or recurrent 
ischemia, and major amputation categories remain 
significant in favor of the surgery results in the FP 
subgroup and overall. The number of amputations 
incurred in the lysis arm was the same whether 
analyzed on an intent-to-treat basis or per protocol. 
Death or major amputation. There was no 
difference in the combined endpoint of death and 
major amputation or death alone overall or in either 
subgroup (Table V). Patients with FP occlusions who 
were randomized to lysis, however, had significantly 
more major amputations than those randomized to 
surgery. Fourteen major amputations were per- 
formed in patients with FP occlusions who underwent 
thrombolysis and none in patients who underwent 
surgical revascularization. The outcome of throm- 
bolysis was not influenced by the duration ofischemic 
symptoms for either subgroup or overall (Table VI). 
Fourteen patients (13.5%) with critical ischemia who 
were randomized to thrombolysis underwent ampu- 
tations versus only one patient (2.2%) who had 
claudication (p < 0.038). In patients who had claudi- 
cation, major amputations occurred at the same 
frequency in the thrombolysis and surgical arms 
(Table VII). In the FP subgroup, 10 of the 14 
amputations occurred in patients with diabetes who 
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Table III. Composite clinical outcome at 30 days, 6 months, and i year (intent o treat) 
Surgery (n ~ 87) 
30 Days 6 Months 1 Year 
Stratum Event n % n % n % 
Thrombolysis (n = 150) 
30 Days 6 Months 1 Year 
n % n % n % 
IF (Count of  patients) 23 - -  23 - -  23 - -  46 - -  46 - -  46 - -  
Composite clinical outcome 4 17.4" 6 26.1" 6 26.1" 25 54.3 25 54.3 27 38.7 
Death 1 4.3 1 4.3 1 4.3 2 4.3 3 6.5 5 10.9 
Major amputation 0 0 0 0 0 0 1 2.2 1 2.2 1 2,2 
Ongoing/recurrent 2 8.7* 4 17.4" 4 17.4" 24 52.2 24 52.2 26 56.5 
ischemia 
Major morbidity 1 4.3 1 4.3 1 4.3 9 19.6 9 19.6 10 21.7 
FP (Count of  patients) 64 - -  64 - -  64 - -  104 - -  104 - -  104 - -  
Composite clinical outcome 25 39.1" 32 50.0* 37 57.8* 66 63.5 79 76.0 80 76.9 
Death 6 9.4 10 15.6 12 18.8 4 3.8 8 7.7 11 10.6 
Major amputation 0 0 0 0* 0 0* 3 2.9 9 8.7 14 13.5 
Ongoing/recurrent 18 28.1" 22 34.4* 26 40.6* 55 52.9 70 67,3 70 67.3 
ischemia 
Major morbidity 14 21.9 15 23.4 16 25.0 26 25.0 28 26.9 28 26.9 
Overall (Count of patients) 87 - -  87 - -  87 - -  150 - -  150 - -  150 - -  
Composite clinical outcome 29 33.3* 38 43.7* 43 49.4* 91 60.7 104 69,3 107 71.3 
Death 7 8.0 11 12.6 13 14.9 6 4.0 11 7,3 16 10.7 
Major amputation 0 0 0 0* 0 0* 4 2.7 10 6,7 15 10.0 
Ongoing/recurrent 20 23.0* 26 29.9* 30 34.5* 79 52.7 94 62.7 96 64.0 
ischemia 
Major morbidity 15 17.2 16 18.4 17 19.5 35 23.3 37 24.7 38 25.3 
*p < 0.05; surgery vs thrombolysis. 
Table IV. Composite clinical outcome at 1 year (per protocol) 
Surgery (n = 77) Thrombolysis (n = 122) 
Stratum Event n % n % p 
IF (Count of  patients) 20 - -  32 - -  - -  
Composite clinical outcome 5 25.0 15 46.9 - -  
Death 0 0 5 15.6 0.0656 
Major amputation 0 0 1 3.1 - -  
Ongoing/recurrent ischemia 4 20.0 14 43.8 0.0828 
Major morbidity 1 5.0 9 28.1 0.0415" 
FP (Count of  patients) 57 - -  90 - -  - -  
Composite clinical outcome 33 57.9 69 76,7 0.0165" 
Death 12 21.1 11 12,2 - -  
Major amputation 0 0 14 15.6 0.0018" 
Ongoing/recurrent ischemia 22 38.6 59 65.6 0.0014" 
Major morbidity 15 26.3 25 27.8 - -  
Overall ( Count of  patients ) 77 - -  122 - -  - -  
Composite clinical outcome 38 49.4 84 68.9 0.0061" 
death 12 15.6 16 13.1 - -  
Major amputation 0 0 15 12.3 0.0014" 
Ongoing/recurrent ischemia 26 33.8 73 59.8 0.0004* 
Major morbidity 16 20.8 34 27.9 - -  
*p < 0.05, surgery vs thrombolysis. 
were randomized to thrombolysis (Table VIII). Pa- 
tients who had diabetes and FP occlusions who were 
randomized tosurgical revascularization had a higher 
mortality rate (32% vs 6%, p = 0.014) at 1 year. This 
finding also was present at 30 days (16% vs 0%, 
p = 0.005) and 6 months (25.8% vs 1.9%, p = 0.002). 
To further explore associations among the risk 
factors of diabetes, critical ischemia, duration of 
ischemia, and median age on the death and major 
amputation endpoint, a series of logistic regression 
models were fitted with the combined IF and FP 
native artery groups. The model that produced the 
best fit to the observed events was one that included 
both diabetes and critical ischemia (p= 0.0325). 
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Tab le  V. Death /major  amputat ion at 1 year ( intent to treat) 
Surgery (n = 87) Thrombolysis (n = 150) 
Stratum Event n % n % p 
IF (Count of patients ) 23 - -  46 
Death/amputation 1 4.3 5 
Death 1 4.3 5 
Major amputation 0 0 1 
FP ( Count of patients ) 64 - -  104 
Death/amputation 12 18.8 22 
Death 12 18.8 11 
Major amputation 0 0 14 
Overall (Count of patients) 87 - -  150 
Death/amputation 13 14.9 27 
Death 13 14.9 16 
Major amputation 0 0 15 
10.9 
10.9 
2.2 
1.2 
10.6 
13.5 0.0011" 
18.0 
10.7 
10.0 0.0013" 
*p < 0.05, surgery vs thrombolysis. 
Tab le  V I .  Death /major  amputat ion at 1 year by durat ion of ischemia ( intent to treat) 
Surgery (n = 85) * Thrombolysis (n = 150) 
0-14 days > 14 days 0-14 days > 14 days 
n % n % n % Stratum Event n % 
IF (Count of patients ) 4 - -  
Death/amputation 0 0 
Death 0 0 
Major amputation 0 0 
FP (Count of patients) 12 - -  
Death/amputation 3 25.0 
Death 3 25.0 
Major amputation 0 0 
Overall ( Count of patients) 16 - -  
Death/amputation 3 18.8 
Death 3 18.8 
Major amputation 0 0 
19 - -  13 - -  33 - -  
1 5.3 0 0 5 15.2 
1 5.3 0 0 5 15.2 
0 0 0 0 1 3.0 
50 - -  19 ~ 85 - -  
9 18.0 4 21.1 18 21.2 
9 18.0 2 10.5 9 10.6 
0 0 2 10.5 12 14.1 
69 - -  32 - -  118 - -  
10 14.5 4 12.5 23 19.5 
10 14.5 2 6.3 14 11.9 
0 0 2 6.3 13 11.0 
*Duration of ischemia not recorded for two patients. 
Because diabetes often appeared as a significant risk 
factor as other prognost ic  factors were added, a 
separate logistic regression model  was run that forced 
treatment and diabetes to be evaluated in combina- 
t ion for an association with the endpoint  o f  death and 
major amputat ion.  This final model  indicated that 
diabetes was a strong risk factor (p = 0.0534),  but  the 
estimated odds ratio o f  1.97 had a wide 95% confi- 
dence interval (0.99 to 3.93). 
D ISCUSSION 
The initial analysis of  the STILE trial demon-  
strated the overall superiority o f  surgical revascular- 
ization for occluded arteries or bypass grafts? This 
result was gleaned from 30-day fol low-up data and 
was based predominant ly  on a marked increase in the 
incidence o f  ongo ing or recurrent ischemia in patients 
who were randomized to thrombolysis.  Important ly,  
a per-protocol  analysis o f  these early findings did not  
change the conclusions o f  the intent-to-treat  nalyses. 
This report  attempts to further analyze native artery 
occlusions as they are most commonly  encountered 
by the vascular surgeon and the interventionalist. 
Two specific anatomic groups composed o f  larger- 
caliber vessels (IF) and distal smaller-caliber vessels 
(FP) were identif ied for the purposes of  analysis. As 
two specific anatomic cohorts,  sufficient numbers 
were available to study the impact o f  various clinical 
parameters on outcome. Smaller cohorts o f  patients 
who had occlusions o f  either the aorta, profunda 
femoris, or  infrapopliteal rterial tree did not  provide 
sufficient power for separate analyses. 
Commonly  noted clinical differences between the 
patients in these two anatomic groups were found: 
namely, individuals who had proximal larger-vessel 
occlusions were more likely to be younger  and smok- 
ers, whereas patients who had FP disease more fre- 
quently had diabetes and a critically ischemic l imb. 
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Table VII. Death or major amputation at 1 year by ischemic symptoms (intent o treat) 
Surgery (n = 86) * Thrombolysis (n = 150) 
Critical ischemia Claudication Critical ischemia Claudication 
Stratum Event n % n % n % n % 
IF (Count of patients) 13 - -  10 - -  30 - -  16 - -  
Death/amputation 1 7.7 0 0 3 10.0 2 12.5 
Death 1 7.7 0 0 3 10.0 2 12.5 
Major amputation 0 0 0 0 1 3.3 0 0 
FP (Count of patients) 39 - -  24 - -  74 - -  30 - -  
Death/amputation 9 23.1 3 12.5 19 25.7 3 10.0 
Death 9 23.1 3 12.5 9 12.2 2 6.7 
Major amputation 0 0 0 0 13 17.61" 1 3.3 
Overall (Count of patients) 52 - -  34 - -  104 - -  46 - -  
Death/amputation 10 19.2 3 8.8 22 21.2 5 10.9 
Death 10 19.2 3 8.8 12 11.5 4 8.7 
Major amputation 0 0 0 0 14 13.5:~ 1 2.2 
*Ischemic symptom not recorded for one patient. 
[Surgery vs thrombolysis, p = 0.004. 
~Surgery vs thrombolysis, p = 0.005. 
Table VIII. Death/major amputation at 1 year by diabetes (intent o treat) 
Surgery (n = 87) Thrombolysis (n = 150) 
Diabetes No diabetes Diabetes No diabetes 
Stratum Event n % n % n % n % 
IF 
FP 
Overall 
(Count of patients) 
Death/amputauon 
Death 
Major amputation 
(Count of patients) 
Death/amputation 
Death 
Major amputataon 
(Count of patients) 
Death/amputation 
Death 
Major amputauon 
7 - -  16 - -  12 - -  34 - -  
0 0 I 6.3 1 8.3 4 11.8 
0 0 1 6.3 i 8.3 4 11.8 
0 0 0 0 0 0 1 2.9 
31 - -  33 - -  53 - -  51 - -  
10 32.3 2 6.1 12 22.6 10 19.6 
10 32.3 2 6.1 4 7.5* 7 13.7 
0 0 0 0 10 18.91" 4 7.8 
38 - -  49 - -  65 - -  85 - -  
10 26.3 3 6.1 13 20.0 14 16.5 
10 26.3 3 6.1 5 7.7* 11 12.9 
0 0 0 0 10 15.4[ 5 5.9 
*Thrombolysis vs surgery, p < 0.05. 
]Surgery vs. thrombolysis p < 0.05. 
Although of no surprise, these findings suggest that 
the patients who were entered into this study are 
typical of the vascular population encountered in 
clinical practice. The racial differences in the ENR 
patients as compared with those who were entered in 
STILE were noted in the initial report? The higher 
incidence of previous bypass grafts in the study limb in 
the ENR group is a finding unique to the native artery 
subgroup. One possible xplanation for this finding is 
that patients who had a failed bypass procedure and 
limited surgical options were preferentially treated 
outside the trial with thrombolysis. This, if true, 
would tend to bias the native artery results in favor of 
a surgical approach. 
As found in the earlier STILE report, the efficacy 
between UK and rt-PA to establish arterial patency 
was similar. The ability of either agent o open IF or 
FP occlusions was equivalent, occurring in 50% to 
60% of cases. Secondary procedures were required in 
more than 50% of patients, but a reduction in the 
magnitude of this procedure was possible in more 
than 50% of patients. These findings are somewhat 
lower than those of many previous nonrandomized 
reports.8-1 
The 30-day, 6-month, and 1-year composite clini- 
cal outcome data demonstrate hat the early analyses 
of this trial for the native artery group persist and 
marginally diverge with longer follow-up. This overall 
advantage for surgical revascularization is heavily 
weighted by the poor thrombolytic results in patients 
who have FP occlusions. In this particular subgroup, 
a higher incidence of ongoing or recurrent ischemia t 
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1 year is accompanied by an increased incidence of 
limb loss. This subgroup finding of unresolved and 
severe ischemia that ultimately results in limb loss is 
the most interesting finding of this report. The 
dichotomy of results between the more proximal IF 
occlusions and distal FP occlusions has been previ- 
ously noted but not particularly emphasized) 2a3 
A persistent criticism of the STILE trial has been 
the design of the intent-to-treat nalysis. It has been 
argued that by including patients who never eceived 
the lyric agent, the results do not truly reflect he value 
ofthrombolytic therapy. A more exclusive approach, 
however, i.e., per-protocol, that includes only those 
patients who actually received the lyric agent creates 
potential statistical inequities and ignores the adverse 
consequences that could result from attempts to 
obtain vascular access and deliver the lyric agent. Such 
concerns ultimately were more theoretic than real 
because analysis by intent-to-treat or per-protocol 
methods preserved the critical findings in the FP 
group and overall. Furthermore, all amputations 
documented on an intent-to-treat basis also were 
present in the per-protocol analysis, which indicates 
that all patients who lost a limb received the lyric 
agent. 
For IF occlusions the per-protocol analysis does 
change the conclusions. The inferior outcome of 
thrombolysis with respect o the composite clinical 
outcome and ongoing or recurrent ischemia vanishes, 
although strong trends favoring surgical revascular- 
ization persist. A new finding is the higher incidence 
of morbid events after thrombolysis. The initial inclu- 
sion of patients who never received the lyric drug 
served to lower the overall percentage of morbid 
events in the lyric arm. Removal of these patients does 
not appreciably alter the absolute incidence of adverse 
events and results in a statistically significant differ- 
ence in the incidence of morbid events between 
surgery and thrombolysis. 
Clinical factors such as duration of ischemia, 
severity of limb ischemia, and diabetes have been 
suggested as important aspects of lytic outcome and 
endovascular therapy in general. 13-is A number of 
authors have shown that thrombolytic therapy per- 
formed within 30 days of symptomatic deterioration 
provides asuperior result compared with patients who 
have a longer duration of ischemic symptoms. 14,13 
The TOPAS (thrombolysis or peripheral arterial sur- 
gery) trial entered only patients who had less than a 
14-day duration ofischemia. Apost hoc analysis of the 
STILE Trial, which stratified all randomized patients 
by duration ofischemia, demonstrated the significant 
benefit of thrombolysis for the acutely (<14 days 
ischemia) ischemic limb, whereas the chronically 
ischemic limbs were best treated with surgical revas- 
cularization.2 
Although 14% of patients in the FP group who had 
a duration ofischemia longer than 14 days eventually 
required amputation after thrombolysis, an equal 
percentage (10%) of amputations occurred in patients 
who had a shorter period ofischemia. Thus unlike the 
post hoc analysis in the initial STILE report, duration 
of ischemia in the FP cohort was not a critical 
determinant of outcome. The limited follow-up and 
the inclusion of bypass grafts as well as all native artery 
occlusions in the initial report most likely accounts for 
this discrepancy. A better understanding ofthe infl u- 
ence of duration of ischemia on outcome will be 
possible when the analysis of the bypass graft cohort is 
completed. 
On the other hand, the severity of limb ischemia 
and diabetes were influential variables when consid- 
ering FP occlusions. Major amputations were clus- 
tered in patients who had diabetes, an FP occlusion, 
and a critically ischemic limb and were treated by 
thrombolysis. Multivariate regression analysis also 
strongly suggested that critical ischemia nd diabetes 
in particular were unique influential variables for both 
surgical revascularization a d thrombolytic therapy. 
From these data, the prone of the patient who 
potentially might benefit from receiving thrombolyric 
therapy can be better characterized. Occlusions that 
involve the larger-diameter proximal arterial tree 
(aorta, iliac, and common femoral) have a higher inci- 
dence of ongoing or recurrent ischemia fter throm- 
bolysis when compared with surgical revasculariza- 
tion, but limb salvage rates are equivalent. This sug- 
gests that thrombolysis, if not successful, may be 
followed by surgical revascularization with a beneficial 
outcome, although an increase in major morbidity 
rates might be encountered. In this subgroup, throm- 
bolysis may be a preferential first option for patients 
who have medical comorbidities that preclude asurgi- 
cal approach, particularly if aortic inflow is required. 
For FP lesions a smaller, more limited application 
of thrombolysis  warranted. Patients with claudica- 
tion who do not have diabetes have equivalent limb 
salvage results when thrombolysis compared with 
surgical therapy. Again, this finding does not imply 
that the initial success of lyric therapy is equivalent, 
because the rate of ongoing or recurrent ischemia was 
higher in the lyric group. Nevertheless, revasculariza- 
tion with an endovascular, lyric approach may be 
preferable for this patient profile with FP occlusions, 
particularly if a surgical approach requires an autog- 
enous conduit hat is scarce or needs to be preserved. 
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The survival benefit of  thrombolysis initially re- 
ported by Ouriel was found to reside exclusively in 
patients who have diabetes and an FP occlusion. 1
Because this benefit was evident at the 30-day time 
point and maintained thereafter, perioperative death 
accounts for this difference. This finding is o f  interest 
for two reasons. First, noncavitary operative proce- 
dures for FP occlusions are purported to carry a lesser 
risk o f  death from cardiovascular causes, yet in this 
clinical trial the mortality rate was significant and was 
lessened by a thrombolytic approach. Secondly, this 
finding suggests that the decision to use surgery or 
lysis in patients who have diabetes and an FP occlusion 
should weigh the possible survival benefit oflysis with 
the limb-salvage benefit o f  surgery. One caveat o this 
consideration is that the survival benefit for patients 
who have diabetes was determined on a post hoc 
analysis. Further prospective studies to confirm this 
finding are thus important. 
Finally, a note o f  caution concerning the findings 
o f  this report should be expressed. This trial was 
designed to enroll 1000 patients but was terminated 
early by a first interim analysis that documented that a 
significant irreversible difference in one primary end- 
point had been reached? The conclusions regarding 
the primary and secondary endpoints analyses and 
subgroups need to be interpreted with this in mind. 
Nevertheless, the results herein provide the strongest 
data to date concerning the relative value of  surgical 
revascularization and thrombolysis for leg ischemia 
caused by a native artery occlusion. 
Surgical revascularization for lower extremity na- 
tive artery occlusions is more effective and durable 
than thrombolysis. Thrombolysis used initially does 
provide a beneficial reduction in the surgical proce- 
dure for a majority o f  patients; however, long-term 
limb salvage rates are inferior, particularly for patients 
who have an FP occlusion, diabetes, or critical limb 
ischemia. 
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DISCUSSION 
Dr. Robert B. Rutherford (Denver, Colo.). I have 
been looking forward to this and other sequels to the 
original presentation of the STILES trial, following which 
many of us were left with the impression that subgroup 
analysis might demonstrate just where the practical advan- 
tages to thrombolytic therapy in leg ischemia re. In that 
regard, this report is disappointing. Even with the addi- 
tional perspective of a 1-year follow-up, the overall clinical 
outcome after thrombolysis i  still clearly inferior to surgery 
for native artery thromboses. The bottom line is that by 
choosing thrombolysis the surgeon will end up, by 1 year, 
with roughly twice the number of patients who have 
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ongoing or recurrent ischemia nd a significantly higher 
amputation rate. The only consolation is a claimed reduc- 
tion in the"level of surgery" in a little more than 50% of 
cases. Even per-protocol analysis, designed to answer the 
criticism that 22% of patients who were randomized to 
thrombolysis did not get it because of access problems, 
modifies ome trends but does not affect he major conclu- 
sions. 
We then are left trying to find out under which specific 
circumstances thrombolytic therapy may be more appropri- 
ate than proceeding directly with surgery, and much of the 
discussion in the manuscript isspent massaging the data to 
this end, and you have already heard the basic trends and 
some tenuous conclusions. In poring over the tables, one 
pattern that struck me that was not mentioned in the 
manuscript was that there seems to be a trade-off of life for 
limb, that is, a lower mortality rate for a higher risk of 
persistent limb ischemia nd amputation when thromboly- 
sis was given in the higher-risk groups, namely patients who 
have diabetes, femoropopliteal occlusions, and critical is- 
chemia. A mortality rate advantage for thrombolytic 
therapy also was seen in the Rochester randomized trial and 
appeared to be in direct proportion to the number of 
surgical revascularizations avoided in high-risk patients. 
Which brings me to the first of three questions I have for 
Dr. Weaver: can you tell us what percent of patients were 
actually saved a surgical revascularization by the use of 
thrombolytic therapy? I have a problem with the trial's 
definition of "a reduction in the level of surgical revascu- 
larization" because it potentially includes a bypass proce- 
dure rather than a foot amputation and a thrombectomy 
and revision rather than a bypass procedure and is therefore 
not, in my view, a discriminating enough secondary end 
point. How do you explain these poor outcomes for 
thrombolytic therapy, where nearly 70% of the thrombolytic 
group died or had a major amputation, recurrent or 
persistent ischemia, or major complications by i year, in the 
light of reports of more than 80% initial success for 
thrombolysis by McNamara and by others? Randomized 
trials tend to bring out the hard truth, but these differences 
in outcome seem irreconcilable. Finally, although it is to be 
expected because native arteries constitute more than 60% 
of the total cases enrolled in the trial that many of the 
findings will be similar to the original report, can you 
summarize for us the major differences between the two 
reports, and, by inference, tell us what to expect in the other 
subgroup, the patients with occluded grafts. 
The question that is bound to arise is whether the 
findings of this trial negate the theoretic and practical 
advantages that have been espoused for thrombolytic 
therapy? I would caution against taking this negative view by 
pointing out that the poor outcomes in this study are 
primarily an indictment against he use of thrombolytic 
therapy for subacute and chronic occlusions, because, 
remember, the duration of ischemia was between 14 days 
and 6 months in close to 80% of these patients, with a mean 
duration of close to 2 months! We should remain open- 
minded about its potential value in earlier cases ofischemia. 
There were not enough of such early cases in this study to 
address this aspect with statistical strength. 
Dr. Fred A. Weaver. Let me just preface my remarks by 
addressing some design issues of the trial. The trial was 
designed as a broad, inclusive trial, including all patients 
who had less than 6 months of ischemic symptoms. In 
retrospect, hat particular approach, as you rightly point 
out, may have diluted important findings in the patient 
cohort who had a shorter duration of ischemia. 
Another important aspect is that the trial closed prema- 
turely. It was designed to enroll 1000 patients, which was 
calculated as being required to reach statistically significant 
endpoints. It was terminated, however, at the first interim 
data analysis because of a significantly increased incidence of 
ongoing recurrent ischemia in the thrombolysis group. 
That very well may be due to the fact that in trying to be 
all-inclusive with the trial we had too many patients who had 
chronic ischemia nd not enough who had acute ischemia. 
Having said that, I think that the trial does provide us 
with some important findings and certainly has the most 
extensive data to date concerning the relative merits of 
thrombolysis and surgical revascularization. 
With regard to the reduction in surgical procedures, 
approximately 55% of the patients enjoyed a reduction in 
the surgical procedure, and about 75% of those procedures 
were endovascular. 
With regard to the other eports in the literature and the 
difference in the findings from this report, I would venture 
to say that those reports are likely from a group that has a 
mixture of bypass grafts and native vessels, with a very 
limited follow-up. None have as all-encompassing a fol- 
low-up as STILE. I think that this suggests that the benefit 
of thrombolytic therapy, something that many of us have 
suspected, initially is quite good but is very short-lived. If
you observe these patients for any length of time, many 
ultimately end up undergoing a surgical procedure. 
With regard to the differences in the preliminary overall 
report, I think the most striking one is the duration of 
ischemia. We did find that in the less-than-14-day group 
there was a benefit in limb salvage rates for thrombolysis. We 
did not see that in the native vessel analysis. I suspect, and I 
think preliminary results would suggest, that most of that 
benefit resides in the bypass grafts, and a more complete 
detailed report of that is forthcoming with 1-year of 
completed follow-up. 
That is the major difference between the two reports. In 
addition, the initial report did not analyze the impact of 
diabetes and the severity ofischemia on treatment outcome. 
Dr. Richard L. Treiman (Los Angeles, Calif.). Could 
you tell us about the complications in your thrombolytic 
group, and especially whether any of the patients had a 
stroke? 
Dr. Weaver. There were, I believe, three incidences of 
intracranial hemorrhage in the thrombolytic group. 
Dr. Treiman. That's a stroke. 
Dr. Weaver. That's a stroke, yes. However, the major 
complication i  the thrombolytic group was actually not 
hemorrhagic omplications, but vascular complications, 
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for example, distal embolization or occlusion of another 
segment that was previously opened. Actually, in the per- 
protocol analysis, which I did not mention in the in- 
terest of time, for the IF group, major morbidity has a 
significantly increased incidence in the thrombolytic 
group. 
Dr. John M. Porter (Portland, Ore.). A very important 
concern in a study such as this is sticking to your endpoints 
and not being guilty of post hoc or data dredging analysis. 
In the initial article in the Annals of Surgery, a significant 
benefit for a duration of symptoms of less than 2 weeks was 
claimed. That was not one of the primary endpoints of the 
study. Thus the entire analysis was data dredging, and that 
can be used only as a hypothesis-seeking exercise, never as a 
hypothesis-testing exercise. 
I see today that you have singled out just the native 
arteries, yet the early report was the entire protocol, native 
arteries and grafts. Singling out just one piece bothers me. 
Was a primary endpoint to analyze these separately, and 
did you specifically have a 1-year analysis as one of your 
primary endpoints? 
Dr. Weaver. As far as the last question is concerned, yes, 
a 1-year analysis was a primary endpoint in the trial. As far as 
native vessel and bypass graft, yes, those subgroup analyses 
were planned to be done, but that was not, as you correctly 
say, a primary endpoint of the trial. 
I think that your points are very well taken. I don't 
know that I would call it data dredging because we all data 
dredge at one time or another. Very few of the randomized 
prospective trials are as pure as they are designed to be, 
particularly when you start talking about technical types 
of trials where you're comparing the ability to technically 
do one procedure over another. As you well know, it is an 
extremely difficult comparison because technical skill and 
talent differs from institution to institution. 
I think that this is a valid attempt to try to make some 
sense out of the data provided by this trial. It certainly has 
more validity than most of the reports currently in the 
literature that drive thrombolytic therapy as a prescribed 
treatment for leg ischemia. 
Dr. Wesley S. Moore (Los Angeles, Calif.). I think the 
most stunning part of your report is the high amputation 
rate among the patients who underwent thrombolysis. I 
think this is a very interesting and perhaps even unique 
finding in this particular study. 
I 'd  like to do a little more data dredging, ifwe may, and 
ask whether you have looked specifically at the patients who 
went on to undergo amputation i the thrombolysis group 
to find out whether there was something peculiar about he 
way in which they were treated. 
For example, were there individuals who were found to 
have very long stenoses in the superficial femoral artery who 
might have benefited from bypass procedures but some- 
body tried to put a bunch of stents in the artery? Have you 
attempted to see why there was a high failure rate? 
Dr. Weaver. That's an excellent question. With a trial of 
this scope and with all the potential possibilities, it is quite 
difficult to obtain that specific assessment. We haven't 
analyzed the data at that level, and maybe that is something 
that we need to go back and look at. At the risk of data 
dredging, we should look at that. 
There is no question that the disparity in the incidence 
ofamputarion i  the thrombolytic group versus the surgical 
group is the most striking finding, and really an unexpected 
finding as far as I 'm concerned. I think that it really requires 
a further look, and that is something that we ought to do 
before we put the closing chapter on this trial. 
Dr. Victor M. Bernhard (Menlo Park, Calif.). This is 
an interesting study, and my question here leads to one of 
the other confounding variables. 
Did any of these patients receive lytic therapy during the 
operative procedure and was this precluded in your proto- 
col? If it was not, how many did receive lyric therapy during 
the operative procedure? 
Dr. Weaver. By protocol, they were not to receive lyric 
therapy at the time of the procedure. If, in fact, they did 
receive lytic therapy, that would be a failure of surgical 
revascularization. 
Dr. Ralph B. Dilley (La Jolla, Calif.). Were there 
institutional differences in the results from the thromboly- 
sis? I have a feeling that the technique of performing 
thrombolysis varies greatly from institution to institution 
and that some may have many more complications than 
others. Did you look at that variable? 
Dr. Weaver. We have not looked specifically at that in 
the full analysis, but I can tell you that there were differ- 
ences, certainly, in the ability to place a guidewire through 
the lesion and for the therapy to be delivered, and that it was 
quite different from institution to institution. It points up 
the difficulty of a trial such as this, which is so technically 
dependent. 
I daresay that if we looked at the surgical aspects a little 
bit closer, we're kind of focusing not only on the throm- 
bolytic aspects but the surgical aspects as well. The differ- 
ences from institution to institution might be tremendous. 
Dr. Jerry Goldstone (San Francisco, Calif.). Is this 
study leading you to use thrombolysis more or less in your 
practice? 
Dr. Weaver. Actually, about the same. We have such a 
high prevalence of diabetes in our population. We have not 
seen the mortality rate benefit hat was found in STILE with 
the use of thrombolysis. 
